December 7, 2020
YESCARTATM (axicabtagene ciloleucel) – a CAR T-cell therapy (or chimeric antigen receptor T-cell therapy) for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, was approved in 2017 by the US Food and Drug Administration (FDA). While YESCARTA is considered a transformative therapy, there has been significant concern regarding access to YESCARTA and other CAR T-cell therapies. The Moran Company (TMC) was asked to use Medicare claims data to identify characteristics of the hospitals that provide, and patients who receive CAR T-cell therapy. This report presents the findings from our analysis using 2018 and 2019 Medicare claims data.